Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia

Summary

The major goal of this project is to investigate established insomnia treatments in a schizophrenia population to see if the improved sleep leads to overall better quality of life. In addition, we hypothesize that the insomnia treatment may also lead to observed improvements in other symptoms associated with schizophrenia such as cognitive impairments, obesity, and negative symptoms.

Timeline

Start

2008-04

Primary completion

2011-04

Completion

2011-04

Outcome

Met primary endpoint

registry analysis (superiority or other test); Eszopiclone Group vs Placebo Group; p = 0.039; Mean Difference (Final Values) -3.8 (95% CI -7.5 to -0.2); Mixed Models Analysis NCT00645944 ↗

Drugs

Indications